TKNO Q3 2024 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$10M+17.2% YoY

Gross Profit

$90,0000.9% margin

Operating Income

-$7M-77.6% margin

Net Income

-$8M-79.0% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-0.4%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$760,000

Balance Sheet

Total Assets

$124M

Total Liabilities

$37M

Stockholders' Equity

$87M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$8M	+17.2%
Gross Profit	$90,000	$1M	-93.9%
Operating Income	-$7M	-$9M	+15.2%
Net Income	-$8M	-$10M	+25.5%

Revenue Segments

Lab Essentials

$7M75%

Clinical Solutions

$2M21%

Other Product

$451,0005%

Geographic Segments

UNITED STATES

$9M95%

Non-US

$519,0005%